THERACRYF PLC Logo

THERACRYF PLC

Develops sulforaphane-based medicines for behavioural brain disorders and oncology.

TCF | IL

Overview

Corporate Details

ISIN(s):
GB00BMVN2C70 (+2 more)
LEI:
213800NO3E6TSTQO8K20
Country:
United Kingdom
Address:
SUITE 24G13 - BLOCK 24, SK10 4TG NETHER ALDERLEY

Description

TheraCryf PLC is a clinical-stage therapeutics company focused on developing a new generation of innovative medicines for behavioural brain disorders and oncology. The company's research and development efforts are centered on sulforaphane-based compounds. Its primary therapeutic focus is on conditions such as opioid and alcohol abuse, binge eating disorder, anxiety, and fatigue. TheraCryf's business strategy is to generate compelling clinical data for its drug candidates with the goal of partnering its programs with larger pharmaceutical companies for late-stage development and commercialization.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-12-03 08:20
Half-year Financial Report
English 203.1 KB
2025-11-26 08:25
Marking Addiction Awareness Week
English 15.6 KB
2025-11-24 08:25
Notice of Results
English 12.5 KB
2025-11-03 08:30
Ox-1 Programme Achieves Manufacturing Milestone
English 16.3 KB
2025-10-10 08:00
World Mental Health Day & Q4 Conference Schedule
English 16.5 KB
2025-09-26 16:45
Holding(s) in Company
English 23.5 KB
2025-09-08 12:38
Holding(s) in Company
English 23.9 KB
2025-09-04 08:00
Ox-1 Patent Grant & Development Programme Update
English 17.3 KB
2025-08-04 16:27
Holding(s) in Company
English 23.3 KB
2025-07-17 08:00
Manufacturing Scale Up of Lead Ox-1 Programme
English 14.1 KB
2025-07-09 16:07
Result of AGM
English 12.3 KB
2025-06-16 17:10
Notice of AGM
English 13.0 KB
2025-06-10 13:32
Ox-1 Investor Presentation
English 11.6 KB
2025-06-03 08:00
Final results for year to 31 March 2025
English 235.9 KB
2025-05-23 08:14
Notice of Results and Ox-1 presentation
English 12.5 KB

Automate Your Workflow. Get a real-time feed of all THERACRYF PLC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for THERACRYF PLC

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for THERACRYF PLC via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

CRONEX.CO.,LTD Logo
A CRO supplying biological species and bio-tissue materials for medical research.
South Korea
215570
C&R Research Inc. Logo
A full-service CRO providing clinical research for pharma and medical device companies.
South Korea
359090
Cte Group Spolka Akcyjna Logo
Diversified firm in HR services, corporate events, and composite materials.
Poland
LPS
curacle co., ltd. Logo
A clinical-stage biopharma developing drugs for intractable vascular diseases.
South Korea
365270
CytoMed Therapeutics Ltd Logo
Clinical-stage developer of off-the-shelf allogeneic cell immunotherapies for cancer.
United States of America
GDTC
Cyxone AB Logo
A clinical-stage biotech developing therapies for autoimmune and autoinflammatory diseases.
Sweden
CYXO
DARWIN AG Logo
Biotechnology firm creating personalized products from individual biological data.
Germany
7V0
DEINOVE Logo
Develops compounds from rare bacteria for cosmetics and new antibiotics.
France
ALDEI
Delta Drone Logo
Develops drone-based systems for the logistics, security, and military sectors.
France
ALDR
Delta-Fly Pharma, Inc. Logo
Biopharmaceutical firm developing novel anticancer drugs from existing components.
Japan
4598

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.